Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Response to the letter by Lai et al. regarding our manuscript “Statin use and pancreatic cancer risk in two prospective cohort studies”

This is a preview of subscription content, log in to check access.

Abbreviations

IPMN:

Intraductal papillary mucinous neoplasm

References

  1. 1.

    Hamada T, Khalaf N, Yuan C, et al. Statin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018;53:959–66.

  2. 2.

    Hamada T, Nowak JA, Milner DA Jr, et al. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J Pathol. 2019;247:615–28.

  3. 3.

    Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology. 2020;158:226–37.e5.

  4. 4.

    Lee JE, Baba Y, Ng K, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011;4:1808–15.

  5. 5.

    Qian ZR, Rubinson DA, Nowak JA, et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4:e173420.

Download references

Acknowledgements

This work was supported in part by a U.S. National Institutes of Health (NIH) grant R35 CA197735 to S.O., and by Hale Center for Pancreatic Cancer Research, NIH/National Cancer Institute (NCI) U01 CA210171, NIH/NCI P50 CA127003, Department of Defense CA130288, Lustgarten Foundation, Pancreatic Cancer Action Network, Stand Up To Cancer, Noble Effort Fund, Peter R. Leavitt Family Fund, Wexler Family Fund, and Promises for Purple to B.M.W.. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in preparation of the manuscript or decision to publish.

Author information

TH had the idea for the article, performed the literature search, and drafted the article. SO and BMW critically revised the article.

Correspondence to Tsuyoshi Hamada.

Ethics declarations

Conflict of interest

BMW declares research funding from Celgene Inc., and consulting for BioLineRx Ltd., G1 Therapeutics Inc., and GRAIL Inc.. This manuscript was not funded by any of those companies. No other conflicts of interest exist. The other authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This reply refers to the article available at https://doi.org/10.1007/s00535-020-01675-x.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hamada, T., Ogino, S. & Wolpin, B.M. Response to the letter by Lai et al. regarding our manuscript “Statin use and pancreatic cancer risk in two prospective cohort studies”. J Gastroenterol (2020). https://doi.org/10.1007/s00535-020-01676-w

Download citation

Keywords

  • Chemoprevention
  • Cohort studies
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Pancreatic neoplasms
  • Risk factors